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Polymorphonuclearleukocytes (PMN)' have been demonstrated to exhibit a cyto-
toxic activity againsttumorcells invitro(1), as well asotherimmunecells, including
cytotoxic lymphocytes, NKcells, and macrophages(2, 3). Forcellular immunereaction
against tumorcells, theseimmune cellsmigrateto tumor-growing sitesfor attacking
tumor cells, thusimplying apossibility thattumorcellsmight produceachemotactic
factor for immune cells. In this regard, Bottazzi et al. (4) have reported that the
neoplastic cells ofmouse or human origin produce chemotactic factors for macro-
phages and there isapositivecorrelationbetween production ofthe factorsbytumor
cellsand the amountofmacrophage infiltrationin tumortissues. It maybe assumed
thatPMN migrate to tumor-growing sitesresponding to tumor-producing chemotactic
factors before the migration ofany other immune cells, since PMN infiltration into
inflammatory sites has been demonstrated to occur at the earliest stage ofinfection
(5). Insome surgical specimens, PMN infiltration has been observed in the primary
tissue oftumors. Infiltration ofPMN has also been demonstrated in lung giant cell
carcinoma (6). This observation has suggested that the tumor cells might release
extracellularly a PMN chemotactic factor.
Thispaper describes the purification ofPMN chemotactic protein (lungcarcinoma-
derived chemotaxin [LUCT]) from the culture fluid ofthe human lung giant cell
carcinoma cell line LU65C (6), and some characterization of LUCT, including
NH2-terminal partial amino acid sequence and amino acid composition. Compar-
isonofamino acid sequenceswasmadebetweenLUCTandotherreported chemotactic
factors and protein deduced from the 3-10C cDNA.
This work wassupported in part by grants from theJapan Health Science Foundation. Address corre-
spondence to K. Suzuki, Department ofAntibiotics, National Instituteof Health, 2-10-35 Kami-Osaki,
Shinagawa-ku, Tokyo 141, Japan.
I Abbreviations used in this paper: CTU, chemotactic migration unit; LUCT, lung carcinoma-derived
chemotaxin; pI, isoelectric point; PMN, polymorphonuclear leukocytes.
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Materials and Methods
LU65C cells (clone C of LU65 cell line) were cultured in 50 ml of Iscove's modified Dul-
becco's medium containing 0.1% BSA supplemented with 100 U/ml penicillin G, 100 Ag/ml
streptomycin, and 0.3% sodium bicarbonate without FCS in a 75-cm' flask. After 4 d of
cultivation, the culture fluid was harvested and centrifuged for 10 min at 1,500 g at 4°C.
The cells were cultured another 4 d with 50 ml of the fresh medium and the culture fluid
was again similarly harvested. Thus, 51.9 liters in a totalvolume of the culture fluidwas frozen
at -80°C in 200 packages. Buffer solutions were used as follows: buffer A, 50 mM sodium
phosphate buffer (pH 7 .4); buffer B, 0.005% BSA (81-028; Miles Scientific Div., Naperville,
IL) was contained in buffer A; buffer C, 0.001% BSA was contained in buffer A; buffer D,
1.0 M NaCl was contained in buffer B; and buffer E, 20 mM sodium phosphate buffer (pH
7 .4). All labware was rinsed with buffer B or C to avoid nonspecific adsorption of LUCT.
After 2.5-3 liters of the culture fluidwas thawed and dialized overnight against water in mem-
brane tubings (mol wt 3,500) (Por3; Spectrum Medical, Los Angeles, CA), the fluid was mixed
with 150 ml of DEAE-Sepharose CL6B equilibrated with the buffer A and gently stirred
for 2 h at 4°C . Then the resin was filtered offon a Kiriyama Roto funnel. After CM-Sepharose
CL6B equilibrated with buffer B as 50 ml slurry (10-ml gel volume) was added to the filtrate
and stirred for 3 h at 4°C, the resin was collected by aspirating with a bottle top filter (7105;
Falcon Labware, Oxnard, CA). After washing the gel with 75 ml of buffer B, protein ad-
sorbed on the gel was eluted with 30 ml of buffer D. Thus, the 3 liters of culture filtrate was
concentrated to 30 ml. The concentrated crude LUCT solution was frozen at -80°C until
for further purification. These procedures were repeated 21 times for concentration ofa total
of 51.9 liters of culture fluid. A total of 750 ml of concentrated crude LUCT solution was
centrifuged for 15 min at 3,000 rpm at VC to eliminate insoluble materials and was dialyzed
against 15 liters ofbuffer A overnight. Successively, LUCT was purified by carboxyl-methylated-
polyvinylalcohol resin, hydrophobic resin, and reversed-phase column on HPLC . SDS-PAGE
was carried out by the method of Laemmli (7) using 1.3 Ag of LUCT. Isoelectric point (pI)
of LUCT was determined by chromatofocusing. LUCT solution containing 0.005% BSA
dialyzed against 25 mM triethylamine HCl buffer (pH 11.0) was applied to a polybuffer ex-
changer PBE 118 column (1.0 ¢ x 15 cm) (Pharmacia Fine Chemicals, Uppsala, Sweden)
equilibrated with 25 mM triethylamine HCl buffer (pH 11 .0); the column was eluted with
225 ml of diluted Pharmalyte (1/45, pH 8.0) at a flow rate of 45 ml/h. Amino acid analysis
ofLUCT (8.5 jug) was performed by an amino acid analyzer (6300E; Beckman Instruments,
Inc., Fullerton, CA) afterhydrolysis with 0.5 ml of 6N HCl in an evacuated sealed tube for
24 h at 1100C. NH2-terminal sequence of LUCT (3 .8 Wg) was directly determined with a
gasphase peptide sequencer (477A; Applied Biosystems, Inc., Foster City, CA). Migration
activity of PMN was determined by the migration distance in a filter (3 Am in pore size)
(Millipore Continental Water Systems, Bedford, MA) using a modified Boyden chamber
method (8). Assay samples at each purification step were dialyzed against 5.0 liters of PBS(-)
overnight before assay. All samples were diluted to one half with a chemotaxismedium, which
consisted of 257o BSA, 1.25 mM CaC12, 0.49 MM MgCl2, 0.41 MM MgS04, 0.1% glucose,
and 0.6% NaHCO3. The diluted sample was placed into the lower compartment of the
chamber, and human PMN suspension (2 x 106 cells/ml) was placed in a mixture of PBS(-)
and chemotaxis medium (1 :1) into the upper compartment and then incubated for 35 min
at 37°C under 5% C02 in air. The leading front distance was expressed as a mean of values
of the final concentration of the sample determined in five microscopic fields. Chemotactic
unit of LUCT was calculated from three parameters; FMLP (10-8 M)-stimulated maximal
migration (FM), minimal migration without chemotactic factor, termed random migration
(RM), and migration induced by LUCT sample (SM). Chemotactic migration unit (CTU)
was defined as 100 x (SM - RM)/(FM - RM). Total CTU in each step was calculated
by multiplying the dilution of a sample for 50 CTU in the dilution-activity curve.
Results and Discussion
Wepurified 35 hgofLUCT asa single peak by areversed-phase column on HPLC
in the final step (Fig. 1). Table I summarizes the results of purification of LUCT.SUZUKI ET AL .
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FIGURE 1.
￿
Reversed-phase column chromatography
onHPLC. Atypical elution profile ofsevenchroma-
tographies . Dialyzed crudeLUCT (200 ml)ofCM-
Sepharose was applied to an Asahipak ES 502C col-
umn (cation exchanger, 7.5 (p x 100 mm) . LUCT
was eluted with a linear gradient of NaCl 0-0.4M
in buffer B at a flow rate of 1.0 ml/min for 45 min,
and then successively elutedwith0.4 and 1.0M NaCl
for 5and 15 min . Combined fractions (48.2 ml)were
supplemented with 2.0Mammonium sulfate and
applied to aTSK gel Phenyl5PWcolumn (7.5 (p x
75mm) equilibratedwith bufferEcontaining 2.0M
ammonium sulfate . LUCT activity was eluted with a
linear gradient of 2.0-0M of ammonium sulfate in
bufferE at a flow rate of0.5 ml/min .The eluate con-
tainingLUCT (4.2 ml)was applied to a reversed-phase
column (Cosmosil5TMS-300, 4.50 x 250mm) and
eluted with CH3CN from 22.3% to 60% containing
0.1% trifluoroacetic acid at a flow rate of0.5 ml/min.
These procedures were repeated for 750 ml of the
concentrated crudeLUCT: ®, chemotactic activity
of a 310-fold diluted fractions with chemotactic
medium ;
￿
, absorbance at 210 nm ;
￿
, a
linear gradient of CH3CN (22.5-60%) .
Molecularmass ofLUCT was determined as a single band at ti10kD by SDS-PAGE
(Fig . 2), and its pI was determined as 10.7 by chromatofocusing . Comparing the
chemotactic activity ofLUCT with that ofFMLP, thechemotactic activity ofLUCT
was 0.75 x 10-9M for ED5o, a higher specific activity than that of the bacterial
chemotactic peptideFMLP (5 x 10-9 M) (8), and comparable with that ofhuman
C5a (10-9 M) (9).
We determined the amino acid sequence of N142-terminal 32 residues of LUCT
and compared it with amino acid sequences of several chemotactic factors (Fig . 3) .
The NH2-terminal sequence ofLUCT was quite different from those ofhuman C5a
and C3b (10) . Recently, PMN chemotactic factors(MDNCF and monokine) from
human peripheral leukocytes stimulated with LPS orCon A were isolated (11, 12) .
NH2-terminal 42- and 20-amino acid sequences ofMDNCF and the monokine
have been determined, respectively . The NH2-terminal amino acid sequence from
TABLE I
Summary of Purification for LUCT
CM-PV, carboxymethylated polyvinylalcohol .
CTU, units in 100-,ul sample = 100 x (SM - RM)/(FM - RM).
Total volume Total activity Total protein Specific activity Fold Yield
m1 CTU' mg CTUlmg %
Culture fluid 51,900 21,200,000 44,600 475 1 100
DEAE-Sepharose 58,600 12,700,000 2,340 5,430 11 .4 59.9
CM-Sepharose 750 5,250,000 26.3 200,000 421 24.8
CM-PV 48 .2 1,990,000 6.0 332,000 699 9.4
Hydrophobic 4.2 714,000 0.571 1,250,000 2,630 3.4
Reversed phase 7.35 570,000 0.035 16,300,000 34,300 2.71898
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FIGURE 2 .
￿
SDS-PAGE ofpurifiedLUCT. LUCT (1 .3 wg)
was applied to SDS-PAGE. Lanes 1 and 5, M, markers;
lane 2, pertussis toxin subunits (28, 23, 22, 11.7 kD) ; lane
3, Kazal's trypsin inhibitor (6 .3 kD) ; lane 4, LUCT.
the sixth amino acid of LUCT was completely identical to the NH2-terminal se-
quence of either chemotactic factor, except for the 11th, 12th, and 31st amino acids.
Considering the homology of the NH2-terminal amino acid sequences, the leuko-
cyte-derived chemotactic factors could be hydrolyzed by atrypsin-like protease, re-
sulting in des(1-5) ofLUCT Moreover, the NH2-terminal amino acid ofLUCT was
Ala, and the NH2-terminal 32-amino acid sequence was extensively homologous
to the 32-amino acid sequence of the protein consisting of 77 amino acids encoded
by 3-10C cDNA derived from mRNA isolated from human leukocytes (13) . LUCT
consisted of 75 (Trp was not tested) amino acids and this amino acid composition
was similar to the reported amino acid composition deduced from the 3-10C cDNA
sequence (Table II) . Schmid andWeissmann (13) have suggested that the NH2-ter-
minal 22 amino acids are the sequence for signal peptide, and therefore, the 23rd
amino acid Ala is the NH2 terminal of the mature protein consisting of 77 amino
acids, strongly suggesting that theLUCTcoding gene structurally resembles the3-10C
cDNA in the carcinoma cells and that LUCT may be initially synthesized as a
99-amino acid protein and then the first 22-amino acid signal peptide may be re-
moved upon extracellular secretion . The NH2-terminal sequence of five amino acids
FIGURE 3 .
￿
A comparison of NH2-terminal amino acid sequence of various chemotactic pro-
teins . 1, LUCT 2, MDNCF; 3, monokine ; 4, 3-10C-encoded protein; 5, 0-thromboglobulin ;
6, platelet factor 4 ; 7, human C5a ; 8, human C36 .Cited from reference 12.
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TABLE II
Amino Acid Composition of LUCT
of LUCT was completely different from the corresponding amino acid sequences
ofboth /3-thromboglobulin and platelet factor 4 (Fig. 3), although both have been
suggested to behomologous to the sequence of3-10C-encodedprotein (13). It should
also benoted that the gene for LUCT is constitutively expressed in the human lung
carcinoma cells without any added stimulant. On the other hand, the synthesis of
the chemotactic factors in human leukocytes has been induced only by stimulation
with LPS or Con A (11, 12).
It has been observed that PMN first infiltrate into inflammatory sites when mice
are intraperitoneally injected with stimulants such as glycogen and casein (5). The
infiltration ofPMNinto tumor-growing sites before infiltration ofmacrophages and
lymphocytes hasbeen also observed (1). Furthermore, Bottazzi et al. (4) havedemon-
strated from using tumorcell lines ofmouse andhuman origin, that there isacorre-
lation between chemotactic activity for mononuclear phagocytes in supernatants of
cultured cells and amount of tumor-associated macrophages in vivo. In addition,
PMN have tumorkillingactivity in vitro (1). Hence, tumor-secreting LUCT might
be involved in the first step of immunosurveillance by PMN in their host-defense
function. Further study is needed to clarify the physiological role of LUCT, espe-
cially in terms of tumor-associated PMN.
Summary
A chemotactic protein forpolymorphonuclear leukocytes (lung carcinoma-derived
chemotaxin [LUCT]) was purified from culture fluid of the human lung giant cell
carcinoma LU65C cells to electrophoretically homogeneous form through five se-
Amino acid (mol) LUCT 3-10C'
0 /0
Lys 12 .49 9 9
His 2 .64 2 2
Arg 8 .05 6 6
Asp 9 .31 7 5
Thr 3 .92 3 2
Ser 7 .36 6 5
Glu 16.62 12 10
Pro 6.35 5 5
Gly 5.60 4 2
Ala 6.98 5 4
1/2Cys 2.15 2 4
Val 4.30 3 6
Met 0.28 0 0
11c 2.40 2 5
Leu 7.47 6 7
Tyr 1 .33 1 1
Phe 2.75 2 3
Trp ND ND 1
Total 100 75 771900 CHEMOTACTIC PROTEIN FOR LEUKOCYTES FROM CARCINOMA CELLS
quential purification steps: DEAE-Sepharose, CM-Sepharose, HPLC on carboxyl-
methylated-polyvinylalcohol resin, hydrophobic, and reversed-phase. The molecular
mass was determined as -10 kD by SDS-PAGE and isoelectric point was 10.7 . The
chemotactic activity (ED5o 0.75 x 10-9 M) was sevenfold more potent than that of
FMLP (5 x 10-9 M) and comparable with that of C5a (10-9 M). N142-terminal
amino acid sequence and amino acid composition of LUCT strongly suggest that
it may be closely related to the putative protein encoded by the cDNA clone (3-1OC)
and almost identical with a part of sequence of the chemotactic factor derived from
stimulated human leukocytes in the 6th to 32nd, but not the N1-12-terminal 5 amino
acids. These results indicate that the carcinoma cells produce LUCT without any
added stimulant and suggest that the previously isolated chemotactic monokines
may correspond to des(1-5) of LUCT in the NH2-terminal region.
The authors are much indebted to Drs. Hirohashi and Shimosato for supply of original carci-
noma cells and valuable suggestions.
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